TuftsCSDD-Logo-Color.jpg
Rising Clinical Trial Complexity Continues to Vex Drug Developers, According to Tufts Center for the Study of Drug Development
May 05, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 5, 2010) - Growing clinical trial complexity continues to challenge the ability of pharmaceutical and biotechnology companies to contain the ever-rising cost of...
TuftsCSDD-Logo-Color.jpg
New Approaches to R&D May Prove Best Path for Drug Developers, According to Tufts Center for the Study of Drug Development
April 06, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 6, 2010) -  Innovative approaches to drug development, including alliances and partnerships, may prove the best way to increase the rate at which the...
TuftsCSDD-Logo-Color.jpg
Regulatory Affairs Workload at Drug Development Firms Has Increased Dramatically, According to Tufts Center for the Study of Drug Development
March 11, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 11, 2010) -  A growing volume of global drug development and commercialization activity during the past decade has dramatically increased the workload for...
TuftsCSDD-Logo-Color.jpg
Tufts Center for the Study of Drug Development Launches New Website to Support Research on Critical Drug Development Issues
January 28, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 28, 2010) - The Tufts Center for the Study of Drug Development, the world's leading, independent authority on the nature and pace of pharmaceutical and biotech drug...
TuftsCSDD-Logo-Color.jpg
Capacity Planning Is Becoming a Critical Success Factor for Drug Developers, According to Tufts Center for the Study of Drug Development
January 26, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 26, 2010) - Growing pressure within the research-based drug industry to bring new products to market faster and more efficiently is transforming clinical trial...
TuftsCSDD-Logo-Color.jpg
U.S. Orphan Product Designations More Than Doubled During Last Decade, According to Tufts Center for the Study of Drug Development
January 20, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 20, 2010) - The number of orphan product designations in the U.S. more than doubled during the last decade, reflecting growing interest by pharmaceutical and biotech...
TuftsCSDD-Logo-Color.jpg
Drug Companies Still Under Pressure to Increase Pace of Development, According to Tufts Center for the Study of Drug Development
January 06, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 6, 2010) - Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success...
TuftsCSDD-Logo-Color.jpg
New Products to Treat Neglected Diseases Are on the Rise, According to Tufts Center for the Study of Drug Development
November 17, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 17, 2009) - New products to treat neglected diseases have received marketing approval from regulatory agencies at a steadily increasing rate in recent years as...
TuftsCSDD-Logo-Color.jpg
Top Performing Drug Developers Are Merging Operational and Strategic Objectives, According to Tufts Center for the Study of Drug Development
October 30, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2009) - Drug companies racing to develop new products to replace drugs coming off patent are finding that success is increasingly tied to the company's ability...
TuftsCSDD-Logo-Color.jpg
Marketing Exclusivity for First-in-Class Drugs Has Shortened to 2.5 Years, According to Tufts Center for the Study of Drug Development
September 09, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2009) - Marketing exclusivity periods for first-in-class drugs have fallen dramatically in recent decades -- from a median of 10.2 years in the 1970s to 2.5...